Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors

Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results

Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer

Peregrine's Bavituximab HCV Phase Ib Study Results Selected for Oral Presentation at Upcoming AASLD Annual Meeting

Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India

Peregrine Pharmaceuticals Adds Pharmaceutical Executive as Head of Business Development for Asia and Europe

Peregrine Receives Deficiency Notice From Nasdaq Regarding Minimum Bid Price Rule

Peregrine Enters Contract Negotiations With U.S. DTRA for Hemorrhagic Fevers

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2007

Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Lung Cancer Patients